Table 5.

Summary^∗ of 2007 IDSA/ATS guidelines for outpatient treatment of community-acquired pneumonia [4].

Conditions	Recommended treatment	Further detail
Region with >25% infection rate with “high-level” macrolide-resistant S. pneumoniae	Consider the nonmacrolide alternatives below
Previously healthy and no risk factors for DRSP	Macrolide (preferred) or doxycycline	Macrolides: azithromycin, clarithromycin, or erythromycin
Comorbidities, including the following:     (i) Recent use of antimicrobials    (ii) Other risks for DRSP	Either respiratory fluoroquinolone or  β-lactam plus macrolide (or doxycycline instead of macrolide)	Fluoroquinolones: moxifloxacin, gemifloxacin, or levofloxacin Preferred β-lactam: high-dose amoxicillin or amoxicillin-clavulanate

^∗This distillation of recommendation is not intended to replace the guidelines, which contain details not shown here; DRSP, drug-resistant S. pneumoniae.